Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
nandrolone decanoate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| steroids, androgens | 1881 | 360-70-3 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Decanoic acid ester of nandrolone that is used as an anabolic agent to prevent or treat WASTING SYNDROME associated with severe chronic illness or HIV infection (HIV WASTING SYNDROME). It may also be used in the treatment of POSTMENOPAUSAL OSTEOPOROSIS.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| S (Water solubility) | 3.09 mg/mL | Bocci G, Oprea TI, Benet LZ |
| S (Water solubility) | 0.00 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Bocci G, Oprea TI, Benet LZ |
| BA (Bioavailability) | 2 % |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK2,MAP2K6,MAP3K7,MAPK10,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CG,PIM2,PRKDC,STK33,SYK,TEK,TGFBR1 | 34 | |||
| kinase-selectivity-class | AXL,EIF2AK3,GRK2,MAP2K6 | 4 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Oct. 5, 1962 | FDA | ASPEN GLOBAL INC |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| MeSH PA | D006728 | Hormones |
| MeSH PA | D045930 | Anabolic Agents |
| MeSH PA | D050071 | Bone Density Conservation Agents |
| MeSH PA | D000728 | Androgens |
| FDA EPC | N0000175824 | Androgen |
| CHEBI has role | CHEBI:75835 | anti-anaemic agent |
| CHEBI has role | CHEBI:77746 | human metabolite |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Anemia in chronic kidney disease | indication | 707323002 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Androgen receptor | Nuclear hormone receptor | AGONIST | CHEMBL | CHEMBL | |||||
| Corticosteroid-binding globulin | Secreted | Ki | 6.14 | CHEMBL | |||||
| Sex hormone-binding globulin | Secreted | Kd | 6.30 | CHEMBL | |||||
| Solute carrier family 22 member 1 | Transporter | IC50 | 4.46 | CHEMBL | |||||
| Androgen receptor | Transcription factor | Ki | 8.68 | CHEMBL | |||||
| Progesterone receptor | Transcription factor | Ki | 7.65 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4018519 | VUID |
| N0000179200 | NUI |
| D00955 | KEGG_DRUG |
| 4018519 | VANDF |
| 4019854 | VANDF |
| C0068395 | UMLSCUI |
| CHEBI:7467 | CHEBI |
| CHEMBL1200946 | ChEMBL_ID |
| CHEMBL1200412 | ChEMBL_ID |
| D000077603 | MESH_DESCRIPTOR_UI |
| DB08804 | DRUGBANK_ID |
| 9677 | PUBCHEM_CID |
| C008580 | MESH_SUPPLEMENTAL_RECORD_UI |
| H45187T098 | UNII |
| 217575 | RXNORM |
| 2095 | MMSL |
| 4555 | MMSL |
| 458 | MMSL |
| 5152 | MMSL |
| 5463 | MMSL |
| d00568 | MMSL |
| 001259 | NDDF |
| 001260 | NDDF |
| 126171003 | SNOMEDCT_US |
| 412253000 | SNOMEDCT_US |
| 86162003 | SNOMEDCT_US |
| C0027368 | UMLSCUI |
| DB13169 | DRUGBANK_ID |
| 9904 | PUBCHEM_CID |
| 295 | INN_ID |
| D009277 | MESH_DESCRIPTOR_UI |
| CHEBI:7466 | CHEBI |
| H45187T098 | INXIGHT DRUGS |
Pharmaceutical products:
None